| Target Price | $43.86 |
| Price | $36.04 |
| Potential |
21.70%
register free of charge
|
| Number of Estimates | 14 |
|
14 Analysts have issued a price target NewAmsterdam Pharma Company 2026 .
The average NewAmsterdam Pharma Company target price is $43.86.
This is
21.70%
register free of charge
$52.50
45.67%
register free of charge
$27.27
24.33%
register free of charge
|
|
| A rating was issued by 19 analysts: 17 Analysts recommend NewAmsterdam Pharma Company to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the NewAmsterdam Pharma Company stock has an average upside potential 2026 of
21.70%
register free of charge
|
| Dec '22 |
2023 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.95 | -2.21 |
| 495.83% | 132.63% | |
| P/E | negative | |
| EV/Sales | 277.33 |
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Citigroup |
Locked
➜
Locked
|
Locked | Oct 17 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Aug 25 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Aug 07 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Jul 17 2025 |
| Citigroup |
Locked
➜
Locked
|
Locked | Jun 17 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Jun 12 2025 |
| Stifel |
Locked
➜
Locked
|
Locked | Jun 10 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Citigroup:
Locked
➜
Locked
|
Oct 17 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Aug 25 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Aug 07 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Jul 17 2025 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Jun 17 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Jun 12 2025 |
|
Locked
Stifel:
Locked
➜
Locked
|
Jun 10 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


